Abstract: The present invention relates to a method and an apparatus for a fast thermo-optical characterisation of particles. In particular, the present invention relates to a method and a device to measure the stability of (bio)molecules, the interaction of molecules, in particular biomolecules, with, e.g. further (bio)molecules, particularly modified (bio)molecules, particles, beads, and/or the determination of the length/size (e.g. hydrodynamic radius) of individual (bio)molecules, particles, beads and/or the determination of length/size (e.g. hydrodynamic radius).
Abstract: The present invention relates to the use of an IGFBP-2 (insulin-like growth factor binding protein-2) molecule for the production of a pharmaceutical composition for the regulation of senescence processes in cells, tissues and/or organs for the maintenance and control of tissue and/or organ functions and/or for the treatment or alleviation of senescence symptoms or early senescence, wherein the IGFBP-2 molecule is selected from the group of an IGFBP-2 polypeptide or of a functional fragment thereof and of a nucleic acid encoding an IGFBP-2 polypeptide or a functional fragment or derivative thereof. Moreover, corresponding methods of treatment are provided. The use of IGFBP-2 in the preparation of a pharmaceutical composition in the medical intervention of cachexia is described.
Type:
Application
Filed:
September 26, 2005
Publication date:
February 4, 2010
Applicant:
LUDWIG-MAXIMILIANS- UNIVERSITÄT MÜNCHEN
Inventors:
Andreas Hõflich, Eckhard Wolf, Ingrid Renner-Müller, Petra Renner, Daniela Diehl, Max Bielohuby, Esther Hessel
Abstract: The present invention relates to a method of identifying a compound for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases, comprising the steps of: (a) bringing into contact a labeled monomeric protein and a differently labeled aggregate of said protein in the (1) presence and (2) absence of a candidate inhibitor of aggregation, (b) determining the amount of co-localized labels, representing the extent of binding of the monomeric proteins to the aggregates of said protein; and (c) comparing the result obtained in the presence and absence of said compound, wherein a decrease of co-localized labels in the presence of said compound is indicative of the compound's ability to inhibit aggregation of said protein. Moreover, the present invention relates to a pharmaceutical composition containing said inhibitor of aggregation as well as to a kit.
Type:
Application
Filed:
May 24, 2005
Publication date:
February 4, 2010
Applicants:
LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT FUR FORDERUNG DER WISSENSCHAFTEN E.V.
Inventors:
Uwe Bertsch, Armin Giese, Hans Kretzschmar, Paul Tavan, Thomas Hirschberger, Jan Bieschke, Petra Weber, Konstanze F. Winklhofer, Jörg Tatzelt, Ulrich F. Hartl, Gerda Mitterregger-Kretzschmar, Tobias Johannes Högen
Abstract: The present invention is in the fields of medicine, public health, vaccine and drug formulation. The invention provides composition formulations comprising a nicotine-carrier conjugate and a stabilizer, wherein said stabilizer comprises a non-reducing disaccharide and a non-ionic surfactant. The composition formulations are stable after a long time of storage at room temperature.
Type:
Application
Filed:
May 11, 2007
Publication date:
September 24, 2009
Applicants:
CYTOS BIOTECHNOLOGY AG, LUDWIG MAXIMILIANS UNIVERSITÄT MÜNCHEN
Inventors:
Rainer Lang, Gerhard Winter, Lorenz Vogt
Abstract: The present invention concerns a method of staining the internal limiting membrane, the vitreous and/or the lens capsule of the eye as well as dyes and medicaments suitable for this method. Such dyes, medicaments and methods are needed in ophthalmic surgery, in particular in macular and/or cataract surgery and/or vitrectomy.
Type:
Application
Filed:
October 12, 2007
Publication date:
August 28, 2008
Applicants:
LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN, FORSCHUNGSVERBUND BERLIN E.V.
Abstract: The present invention is directed to a reagent for use in the preparation of organomagnesium compounds as well as to a method of preparing such organomagnesium compounds. The present invention furthermore provides a method of preparing functionalized or unfunctionalized organic compounds as well as the use of the reagents of the present invention in the preparation of organometallic compounds and their reaction with electrophiles. Finally, the present invention is directed to the use of lithium salts—LiY in the preparation of organometallic compounds and their reactions with electrophiles and to an organometallic compound which is obtainable by the disclosed method.
Abstract: The present invention is directed to a reagent for use in the preparation of organomagnesium compounds as well as to a method of preparing such organomagnesium compounds. The present invention furthermore provides a method of preparing functionalized or unfunctionalized organic compounds as well as the use of the reagents of the present invention in the preparation of organometallic compounds and their reaction with electrophiles. Finally, the present invention is directed to the use of lithium salts—LiY in the preparation of organometallic compounds and their reactions with electrophiles and to an organometallic compound which is obtainable by the disclosed method.
Abstract: The present invention is directed to a reagent for use in the preparation of organomagnesium compounds as well as to a method of preparing such organomagnesium compounds. The present invention furthermore provides a method of preparing functionalized or unfunctionalized organic compounds as well as the use of the reagents of the present invention in the preparation of organometallic compounds and their reaction with electrophiles. Finally, the present invention is directed to the use of lithium salts—LiY in the preparation of organometallic compounds and their reactions with electrophiles and to an organometallic compound which is obtainable by the disclosed method.
Abstract: The invention relates to novel nucleic acids encoding a fibroblast growth factor-23(FGF23) and proteins encoded thereby, mutations in which are associated with autosomal dominant rickets (ADHR). The invention further relates to methods of diagnosing and treating hypophosphatemic and hyperphosphatemic disorders comprising inhibiting or stimulating, respectively, the biological activity of FGF23 in a patient. The invention also relates to methods of treating osteoporosis, dermatomyositis, and coronary artery disease comprising stimulating the biological activity of FGF23 in a patient.
Type:
Application
Filed:
March 4, 2003
Publication date:
September 25, 2003
Applicant:
Advanced Research & Technology Institute and Ludwig-Maximilians-Universitat Munchen
Inventors:
Michael Econs, Ken White, Tim Matthias Strom, Thomas Meitinger
Abstract: The invention relates to novel nucleic acids encoding a fibroblast growth factor-23(FGF23) and proteins encoded thereby, mutations in which are associated with autosomal dominant rickets (ADHR). The invention further relates to methods of diagnosing and treating hypophosphatemic and hyperphosphatemic disorders comprising inhibiting or stimulating, respectively, the biological activity of FGF23 in a patient. The invention also relates to methods of treating osteoporosis, dermatomyositis, and coronary artery disease comprising stimulating the biological activity of FGF23 in a patient.
Type:
Application
Filed:
July 10, 2001
Publication date:
October 24, 2002
Applicant:
Advanced Research & Technology Institute and Ludwig-Maximilians-Universitat Munchen
Inventors:
Michael Econs, Ken White, Tim Matthias Strom, Thomas Meitinger